A retrospective analysis of 1,230 patients transplanted for acute myeloid leukemia in first complete remission (CR1), patients conditioned with IV-Bu and cyclophosphamide had significantly better leukemia-free survival than patients who received cyclophosphamide and TBI (RR=0.70; 95% CI: 0.55-0.88; p=0.003).
IV Busulfan Better Than TBI in HCT for AML in CR1
Oct 2013